Biomarkers /
ERCC5
Overview
Excision repair cross-complementation group 5 (ERCC5) is a gene that encodes a protein that is involved in DNA excision repair following UV-induced damage. Missense mutations, silent mutations, nonsense mutations, and frameshift deletions are observed in cancers such as parathyroid cancer, colon cancer, and endometrial cancer.
ERCC5 is altered in 2.11% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in ERCC5 are ERCC5 Mutation (1.63%), ERCC5 Amplification (0.20%), ERCC5 Loss (0.13%), ERCC5 E548K (0.03%), and ERCC5 P571L (0.02%) [3].
Clinical Trials
Significance of ERCC5 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.